Effective treatment of ocular HSK with a human apolipoprotein E mimetic peptide in a mouse eye model

被引:32
作者
Bhattacharjee, Partha S. [1 ]
Neumann, Donna M. [1 ]
Foster, Timothy P. [2 ]
Clement, Christian [1 ]
Singh, Gyanendra [1 ]
Thompson, Hilary W. [1 ,4 ,5 ]
Kaufman, Herbert E. [1 ,2 ,3 ,4 ]
Hill, James M. [1 ,2 ,3 ,4 ]
机构
[1] Louisiana State Univ, Hlth Sci Ctr, Sch Publ Hlth, Dept Ophthalmol, New Orleans, LA USA
[2] Louisiana State Univ, Hlth Sci Ctr, Sch Publ Hlth, Dept Microbiol Immunol & Parasitol, New Orleans, LA USA
[3] Louisiana State Univ, Hlth Sci Ctr, Sch Publ Hlth, Dept Pharmacol, New Orleans, LA USA
[4] Louisiana State Univ, Hlth Sci Ctr, Sch Publ Hlth, Ctr Neurosci, New Orleans, LA USA
[5] Louisiana State Univ, Hlth Sci Ctr, Sch Publ Hlth, Biostat Sect, New Orleans, LA USA
关键词
D O I
10.1167/iovs.08-2077
中图分类号
R77 [眼科学];
学科分类号
100212 [眼科学];
摘要
PURPOSE. To evaluate efficacy of the small apolipoprotein E (apoE) mimetic dimer peptide (apoEdp) in the treatment of herpetic stromal keratitis in a mouse ocular model and determine its therapeutic effects against HSV-1-induced inflammatory cytokines. METHODS. Female C57B1/6 mice were corneally infected with HSV-1 strain KOS-GFP; topical treatment was initiated 24 hours after infection and continued for 10 consecutive days. Treatment groups were 1% apoEdp, 1% trifluorothymidine (TFT), and phosphate-buffered saline (PBS). The incidence and severity of stromal keratitis were monitored by slit lamp examination in a masked fashion. Infectious HSV-1 titer in eye swabs and alteration in inflammatory cytokines were determined in the early postinfection period by real-time RT-PCR. RESULTS. One percent apoEdp treatment, which significantly reduced the incidence and severity of HSK, was equal to the effect of 1% TFT; both groups had significantly lower incidence and severity than the placebo treatment group. The in vivo mouse ocular model results of apoEdp therapy correlated with accelerated clearance of virus from eye swabs. Topical 1% apoEdp treatment in mice significantly downregulated gene expression of mouse proinflammatory cytokines. CONCLUSIONS. These results suggest that topical treatment with apoE peptide has efficacy against HSK through anti-HSV-1 and anti-inflammatory activities.
引用
收藏
页码:4263 / 4268
页数:6
相关论文
共 45 条
[1]
Heparin regulates vascular endothelial growth factor165-dependent mitogenic activity, tube formation, and its receptor phosphorylation of human endothelial cells -: Comparison of the effects of heparin and modified heparins [J].
Ashikari- Hada, S ;
Habuchi, H ;
Kariya, Y ;
Kimata, K .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (36) :31508-31515
[2]
Apolipoprotein E modulates establishment of HSV-1 latency and survival in a mouse ocular model [J].
Bhattacharjee, Partha S. ;
Neumann, Donna M. ;
Stark, David ;
Thompson, Hilary W. ;
Hill, James M. .
CURRENT EYE RESEARCH, 2006, 31 (09) :703-708
[3]
BHATTACHARJEE PS, EXP EYE RES
[4]
Counteracting corneal immunoinflammatory lesion with interleukin-1 receptor antagonist protein [J].
Biswas, PS ;
Banerjee, K ;
Zheng, M ;
Rouse, BT .
JOURNAL OF LEUKOCYTE BIOLOGY, 2004, 76 (04) :868-875
[5]
Involvement of apolipoprotein E in the hematogenous route of herpes simplex virus type 1 to the central nervous system [J].
Burgos, JS ;
Ramirez, C ;
Sastre, I ;
Bullido, MJ ;
Valdivieso, F .
JOURNAL OF VIROLOGY, 2002, 76 (23) :12394-12398
[6]
LOCALIZATION OF A DOMAIN IN APOLIPOPROTEIN-E WITH BOTH CYTOSTATIC AND CYTOTOXIC ACTIVITY [J].
CLAY, MA ;
ANANTHARAMAIAH, GM ;
MISTRY, MJ ;
BALASUBRAMANIAM, A ;
HARMONY, JAK .
BIOCHEMISTRY, 1995, 34 (35) :11142-11151
[7]
HIV-infected subjects with the E4 allele for APOE have excess dementia and peripheral neuropathy [J].
Corder, EH ;
Robertson, K ;
Lannfelt, L ;
Bogdanovic, N ;
Eggertsen, G ;
Wilkins, J ;
Hall, C .
NATURE MEDICINE, 1998, 4 (10) :1182-1184
[8]
CUBITT CL, 1995, INVEST OPHTH VIS SCI, V36, P330
[9]
The receptor-binding region of human apolipoprotein E has direct anti-infective activity [J].
Dobson, CB ;
Sales, SD ;
Hoggard, P ;
Wozniak, MA ;
Crutcher, KA .
JOURNAL OF INFECTIOUS DISEASES, 2006, 193 (03) :442-450
[10]
DYER CA, 1995, J LIPID RES, V36, P80